These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33630021)

  • 1. Overcoming Barriers to Treatment of Opioid Use Disorder.
    Olsen Y; Fitzgerald RM; Wakeman SE
    JAMA; 2021 Mar; 325(12):1149-1150. PubMed ID: 33630021
    [No Abstract]   [Full Text] [Related]  

  • 2. Removing One Barrier to Opioid Use Disorder Treatment: Is It Enough?
    Weimer MB; Wakeman SE; Saitz R
    JAMA; 2021 Mar; 325(12):1147-1148. PubMed ID: 33630020
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlling the Swing of the Opioid Pendulum.
    Comerci G; Katzman J; Duhigg D
    N Engl J Med; 2018 Feb; 378(8):691-693. PubMed ID: 29466151
    [No Abstract]   [Full Text] [Related]  

  • 4. Buprenorphine to treat opioid use disorder: A practical guide.
    Nissly T; Levy R
    J Fam Pract; 2018 Jun; 67(9):544-548. PubMed ID: 30216393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 6. Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021.
    Thakrar AP; Alexander GC; Saloner B
    JAMA Netw Open; 2021 Dec; 4(12):e2138807. PubMed ID: 34905010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
    Chou R; Ballantyne J; Lembke A
    Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
    [No Abstract]   [Full Text] [Related]  

  • 9. When Prescribing Isn't Enough - Pharmacy-Level Barriers to Buprenorphine Access.
    Cooper HLF; Cloud DH; Young AM; Freeman PR
    N Engl J Med; 2020 Aug; 383(8):703-705. PubMed ID: 32813945
    [No Abstract]   [Full Text] [Related]  

  • 10. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of Drugs Used to Treat Opioid Use Disorder.
    Aschenbrenner DS
    Am J Nurs; 2018 Aug; 118(8):25. PubMed ID: 30048283
    [No Abstract]   [Full Text] [Related]  

  • 12. Medical specialty of buprenorphine prescribers for pregnant women with opioid use disorder.
    Hollander MAG; Jarlenski MP; Donohue JM; Cole ES; Kelley D; Krans EE
    Am J Obstet Gynecol; 2019 May; 220(5):502-503. PubMed ID: 30703340
    [No Abstract]   [Full Text] [Related]  

  • 13. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period.
    Lembke A; Ottestad E; Schmiesing C
    Pain Med; 2019 Mar; 20(3):425-428. PubMed ID: 29452378
    [No Abstract]   [Full Text] [Related]  

  • 14. Expanding Access to Medications for Opioid Use Disorder: Federal Policy Is Only a Part of the Solution.
    Heidari O; Banta-Green CJ
    Am J Public Health; 2024 Jul; 114(7):693-695. PubMed ID: 38838294
    [No Abstract]   [Full Text] [Related]  

  • 15. Innovations in efforts to expand treatment for opioid use disorder.
    Sigmon SC
    Prev Med; 2019 Nov; 128():105818. PubMed ID: 31445112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to treatment for opioid use disorders: Medical student preparation.
    McCance-Katz EF; George P; Scott NA; Dollase R; Tunkel AR; McDonald J
    Am J Addict; 2017 Jun; 26(4):316-318. PubMed ID: 28394437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common elements in opioid use disorder guidelines for buprenorphine prescribing.
    Atkinson TJ; Pisansky AJB; Miller KL; Yong RJ
    Am J Manag Care; 2019 Mar; 25(3):e88-e97. PubMed ID: 30875177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
    Ferrara MM
    Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140
    [No Abstract]   [Full Text] [Related]  

  • 19. ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.
    Marino R; Perrone J; Nelson LS; Wiegand TJ; Schwarz ES; Wax PM; Stolbach AI
    J Med Toxicol; 2019 Oct; 15(4):307-309. PubMed ID: 31414402
    [No Abstract]   [Full Text] [Related]  

  • 20. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
    Shover CL
    Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.